

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer

Supportive Care

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0



Supportive Care

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

- **Version 2002:**
Diel
- **Version 2003–2008:**
**Bischoff / Diel / Heinrich / von Minckwitz
/ Oberhoff / Schaller / Scharl**
- **Version 2009:**
Bauerfeind / Jackisch

Further
Information

References

Indications for Erythropoiesis-Stimulating Factors (ESF)

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

	Oxford / AGO LoE / GR		
➤ Asymptomatic anaemia	1a	B	-
➤ Symptomatic anaemia	1b	A	+
➤ Improvement of outcome (DFS, OS)	2b	B	--
➤ Primary prophylaxis of chemotherapy-induced anaemia	1b	A	-
➤ In dose-dense / dose-escalated CT (ETC)	1b^a	A	+
➤ Treatment and secondary prophylaxis of CT induced anaemia	1a	A	+
➤ Treatment start at Hb-levels approaching < 10 g/dL	1a	A	+
➤ Target Hb 11–12 g/dL	1a	A	+
➤ Thromboembolic events increased with ESF	1a	A	

Further
Information

References

Myeloid Growth Factors

Oxford AGO

LoE / GR

- | | |
|--|---|
| <ul style="list-style-type: none"> ➤ Primary prophylaxis for expected febrile neutropenia (FNP) <ul style="list-style-type: none"> ➤ 10–20% expected risk for FNP <ul style="list-style-type: none"> ➤ In case of individual risk factors ➤ > 20% (e.g. DAC, dose-dense CT) ➤ Secondary prophylaxis during chemotherapy (previous FNP or neutropenia Grade IV > 7 days) ➤ Therapeutic usage for FNP ➤ Start related to chemotherapy and duration <ul style="list-style-type: none"> ➤ Pegfilgrastim day 2 q 3 w ➤ Filgrastim/Lenograstim from day 1–3 until ANC > 2–3 x 10⁹ | <p>1b B +/-</p> <p>3b C +</p> <p>1a A ++</p> <p>1b B ++</p> <p>1a A +/-</p> <p>1b A ++</p> <p>1b A ++</p> |
|--|---|

Further
Information

References

Amifostin

**Oxford AGO
LoE /GR**

- **Reduction of cytotoxic side effects
of chemotherapy and / or radiotherapy** **2b B +/-**

Further
Information

References

Dexrazoxane

Oxford AGO
LoE / GR

- | | | | |
|--|-----------|----------|-----------|
| ➤ Treatment of anthracycline extravasation | 2b | B | + |
| ➤ In combination with anthracyclines for cardiac protection | 1a | B | + |
| ➤ In cardiac risk patients | | | |
| ➤ Dexrazoxane | 1b | B | + |
| ➤ Consider alternative regimens (anthracycline-free, liposomal) | 5 | D | ++ |

Further
Information

References

Antiemetic Therapy

Oxford AGO
LoE / GR

- | | | | |
|--|-----------|----------|-----------|
| ➤ After assessment of emetic potential of chemotherapy protocol | 5 | D | ++ |
| ➤ Neurokinin 1 receptor antagonists | 2a | B | + |
| ➤ Dexamethasone | 2a | B | + |
| ➤ 5-HT₃-antagonists | 2a | B | + |
| ➤ Metoclopramide | 3b | C | + |

Further
Information

References